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Abstract: Vesicular stomatitis virus (VSV), an enveloped, nonsegmented, negative-stranded 
RNA virus, is being tested by several laboratories as an antitumor agent. Unfortunately, viral 
infection of the central nervous system (CNS) has been observed by many groups following 
administration to tumor-bearing animals. In rodents, VSV encephalitis is characterized by 
weight-loss, paralysis, and high mortality. In order to provide protection from VSV infection 
of the CNS after therapeutic administration, we have attenuated VSV by the introduction of 
the gene encoding the proinflammatory cytokine interleukin (IL)-23, and designated the new 
virus VSV23. We hypothesize that while VSV23 is replicating within tumors, resulting in tumor 
destruction, the expression of IL-23 will enhance host antitumor and antiviral immune responses. 
In the event that the virus escapes from the tumor, the host’s immune system will be activated 
and the virus will be rapidly cleared from healthy tissue. Experimental VSV23 infection of the 
CNS is characterized by decreased viral replication, morbidity, and mortality. VSV23 is capable 
of stimulating the enhanced production of nitric oxide in the CNS, which is critical for elimina-
tion of VSV from infected neurons. Intraperitoneal administration of VSV23 stimulates both 
nonspecific natural killer cell, virus-specific cytolytic T lymphocyte and memory virus-specific 
proliferative T cell responses against wild-type VSV in splenocytes. Furthermore, VSV23 is able 
to replicate in, and induce apoptosis of tumor cells in vitro. These data indicate that VSV23 is 
immunogenic, attenuated and suitable for testing as an efficacious and safe oncolytic agent.
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Introduction
Vesicular stomatitis virus (VSV), a prototypical member of the genus Vesiculovirus, 
is a naturally occurring virus which is transmitted by sand flies to livestock and causes 
the eponymous small oral rashes. VSV infections in humans tend to be asymptomatic 
and generally limited to researchers and livestock handlers. Therefore, most humans 
are seronegative.1,2 VSV is extremely sensitive to antiviral host cell interferon (IFN) 
responses.3–5 IFNs induced by VSV infection may help eliminate the virus and protect 
otherwise uninfected tissues, however blocking of host nuclear export by the VSV 
M protein is associated with viral evasion of IFN-induced cellular defenses.6–8 VSV 
rapidly replicates and induces apoptosis in cells that have compromised interferon 
pathways, a common characteristic of many tumor cell lines.9–15 These traits make 
VSV an attractive agent for utilization as an oncolytic agent.
Inoculation of immunocompetent mice with high doses of VSV by the intramus-
cular, subcutaneous, or intraperitoneal (IP) routes generally leads to limited viral 
replication and no apparent disease.16–18 Intravenous inoculation of immunocompetent 
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mice with high doses of VSV can lead to very limited viral 
replication in the periphery, but can cause central nervous 
system (CNS) pathology if the virus gains access to the 
brain despite the induction of antibody responses.17,19,20 
Immunocompromising the IFN signaling cascade or T cell 
deficiency leads to death following host infection.18,21–23 
Studies have shown that if VSV infection of tumors reaches 
the host’s CNS, viral encephalitis will result.10,24 Infection 
via intranasal (IN) administration results in severe pathol-
ogy characterized by weight loss, hind-limb paralysis, and 
death.16,25,26 Immunocompetent mice develop high morbid-
ity and mortality following IN infection at viral doses as 
low as 200 plaque-forming units (PFU), succumbing to 
infection between 6–11 days postinfection (PI). A recent 
study in nonhuman primates demonstrated significant 
neuropathology following intrathalamic inoculation.27 The 
neurotropism and neuropathology of VSV necessitates the 
development of an attenuated virus if VSV is to be used 
as a therapeutic.
During VSV infection of the CNS, neutrophils, natural 
killer (NK) cells, macrophages, and T cells are recruited to 
attack the virus at the site of infection.18,26,28–30 Plasmacytoid 
dendritic cells (pDC) in the lymph nodes and spleen respond 
to VSV infection through TLR 7.31,32 Within 36 hours of 
infection, neutrophils are recruited from circulation;26,29 
NK cells are detected at day three and onward in the brains 
of VSV infected hosts.26,29,33 Neutrophils play an early role in 
control of the rate of infection, as they produce nitric oxide 
(NO), OONO–, lipid mediators, as well as pro-inflammatory 
chemokines and cytokines, critical components of immunity 
in controlling early infections of the CNS.28
VSV proteins, processed by antigen-presenting cells, 
result in the induction of the adaptive immune response: 
CD4+ and CD8+ T cells as well as anti-VSV antibodies.34–38 
The essential role of MHC II-restricted viral glycoprotein 
CD4 effector cells in recovery from viral encephalitis was 
shown in the BALB/cH-2dm2 mouse strain.35 Neutralizing 
antibodies are directed against the glycoprotein with IgM 
produced first and IgG second.20,39
Interleukin (IL)-23 is a heterodimeric member of the 
IL-12 family of cytokines composed of a p40 subunit shared 
with IL-12 and a unique p19 subunit. A heterodimeric receptor 
IL-23R includes a unique chain and the IL-12Rβ1 subunit.40 
IL-23R is expressed on the surface of immune cells including 
T cells, NK cells, macrophages, and dendritic cells. Binding 
of IL-23 to IL-23R results in signaling through the Jak, Tyk, 
signal transducers and activators of transcription (STAT) 
pathways and the transcription factor RoRγT.41,42 IL-23 is 
produced by macrophages and dendritic cells.43 IL-23 also 
plays a role in the differentiation of proinflammatory T cells 
secreting IL-17.44 The IL-23/IL-17 cascade has been asso-
ciated with several inflammatory illnesses including 
rheumatoid arthritis, psoriasis, and experimental allergic 
encephalomyelitis (EAE).45–48
Antimetastatic and antitumor properties have been 
associated with IL-23 and IL-12, however the therapeutic 
use of IL-12 in cancer treatment has been compromised by 
side-effects associated with the induction of IFN-γ.49–54 The 
antitumor effects associated with IL-23 are attributed to pro-
duction of tumor necrosis factor-α (TNF-α) (not IFN-γ), and 
result in enhanced effectiveness of CD8+ T cells.55 Experiments 
indicated that depletion of NK cells had no affect on 
the antitumor activity of IL-23 as determined by tumor 
growth rate, however CD8+ T cell depletion significantly 
compromised the ability of naive mice to reject implanted 
tumors and limit tumor growth rates.56 Experiments con-
ducted with IL-23-transduced CT26 cells and B16F1 
tumor cells have shown increased antitumor memory T cell 
responses and decreased lung metastases in vivo.52 Experi-
ments conducted with the murine mammary cancer cell 
line MA891, have shown that expression of IL-23 through 
retrovirus transduction resulted in increased antitumor CTL 
effectors.57
Based on IL-23’s proinflammatory activity in the CNS, 
we hypothesized that a recombinant VSV which expressed 
IL-23 would be attenuated in the CNS while still being 
fully immunogenic in the periphery. Additionally, this 
recombinant virus would maintain (and possibly enhance) 
its oncolytic capacity. To test this hypothesis we have gener-
ated a recombinant VSV that expresses a single chain IL-23 
designated VSV23. Assays of innate and adaptive immune 
responses following parenteral challenge were performed 
to determine the immunogenicity of the virus. VSV23 has 
also been tested for attenuation in vitro and in vivo in the 
in model of VSV encephalitis. Finally the ability of VSV23 
to infect and kill a mammary derived tumor cell line in vitro 
has been determined.
Materials and methods
Plasmid production
To produce a recombinant VSV that expresses IL-23, 
single-chain IL-23 (scIL23) comprised of the p40 and 
p19 subunits joined with a flexible linker [(Gly
4
Ser)
3
] was 
amplified by PCR from plasmid pCEP4-scIL23Ig, a generous 
gift from Dr Maria Laura Belladonna (University of Perugia, 
Italy).58 This reaction removed an Ig binding region from 
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the 3’ end and introduced XhoI and SpeI restriction sites at 
the 5′ and 3′ ends respectively, as well as a stop codon at the 
3′ end. The forward primer sequence was 5′-TAGTCCTC-
GAGATGTGTCCTCAGAAGCTAACCATCT-3′ and the 
reverse primer was 5′-TATGAACTAGTCTAAGCTGTTG-
GCACTAAGGGCT-3′. The amplified region was cloned into 
the VSV expression vector (pXN2) (the generous gift of Jack 
Rose, Yale University School of Medicine, New Haven, CT) 
and the resultant plasmid was designated pXN2-scIL23.59
To generate a control virus containing the IL-23 coding 
sequence, scIL23 was amplified from pCEP4-scIL23Ig, 
restriction digested with KpnI and XbaI, then ligated with 
the intermediate vector pSP73. Three stop codons were 
introduced into the p40 subunit using the Quikchange Site-
Directed Mutagenesis Kit (Stratagene, La Jolla, CA) per 
manufacturer’s directions. The mutagenesis forward primer 
was 5′-ACTCCGGACGGTTCACGTGATGATGACTG-
GTGCAAAGAAACATGG-3′ and the reverse primer 
was 5′-CCATGTTTCTTTGCACCAGTCATCATCACGT-
GAACCGTCCGGAGT-3′. XL1-Blue cells (Strategene) 
were transformed with the mutagenesis reaction polymerase 
chain reaction (PCR) product and plated on LB-Amp plates. 
Plasmids isolated from colonies and correct mutations were 
identified by sequencing at the New York University (NYU) 
Sequencing Core. Positive sequences were then subjected 
to PCR and subsequent cloning to the pXN2 plasmid as 
described above. The resultant plasmid was designated 
pXN2-scIL23ST.
Cell lines
BHK-21 baby hamster kidney cells, JC murine mammary 
gland adenocarcinoma-derived cells, L929 murine adipocytes 
and NB41A3 murine neuroblastoma cells were all purchased 
from the American Type Culture Collection (Manassas, VA). 
BHK-21 cells were grown in minimum essential media 
(Mediatech, Manassas, VA) with 1% nonessential amino 
acids, 1% penicillin-streptomycin (pen-strep) and 10% 
fetal bovine serum (FBS), JC cells grown in RPMI1640 
(Mediatech) with 1% pen-strep and 10% FBS, L929 cells 
grown Dulbecco’s modified Eagles’ medium (Mediatech) 
with 1% pen-strep, 1% HEPES buffer, 1% L-glutamine and 
10% fetal bovine serum (FBS), NB41A3 grown in F-12K 
media (Mediatech) with 2.5 FBS and 15% horse serum.
Recombinant VSV rescue
Recombinant VSVs (rVSVs) were rescued in BHK-21 cells 
using the previously described reverse genetics method.59 
Briefly, cells were infected with vaccinia virus expressing the 
T7 RNA polymerase, then transfected with pXN2-scIL23, 
pXN2-scIL23ST, or pXN2 to produce VSV23, VSVST, and 
VSVXN2 respectively. In addition, plasmids encoding N, P, 
and L proteins were co-transfected using LipofectAMINE 
2000 (Invitrogen, Carlsbad, CA). Vaccinia virus was removed 
by filtration through a 0.20 µm filter after 48 hours of incuba-
tion. Filtrate was added to fresh BHK-21 cells. Subsequently, 
individual clones were plaque purified and used for produc-
tion of viral stocks. Titers of rVSV were determined by plaque 
assay on L929 cells.
One-step growth curve
L929 cells were grown to 90% confluence in 24-well plates 
and infected with VSV23, VSVST, VSVXN2, or VSVwt 
(Indiana serotype, San Juan strain, originally obtained from 
Alice S. Huang, then at The Childrens’ Hospital, Boston, MA) 
at a multiplicity of infection (MOI) = 1 for 30 minutes at 
room temperature (RT). Wells were washed with HBSS to 
remove unadsorbed virus and media was added to each well. 
Aliquots of media were removed at 1.5, 3, 6, 12, and 24 hours 
and stored at -80 °C. Viral titers were determined by plaque 
assay on L929 cells. All samples were assayed in triplicate 
and the experiment repeated twice.
eLIsA for virally produced IL-23
HK-21 cells were infected with VSV23, VSVST, or 
VSVXN2 at MOI = 0.1 and incubated overnight at 37 °C 
and 5% CO
2
. Uninfected BHK-21 cells were used as a 
negative control. Supernatants were harvested and subjected 
to ELISA analysis specific for the p40 subunit of IL-23 using 
the mouse IL-12/IL-23 Total p40 ELISA kit (eBioscience, 
San Diego, CA).
Animals
All procedures involving animals were approved by and per-
formed according to the guidelines of The University Animal 
Welfare Committee of New York University. Six-week old 
male BALB/cAnNTac (BALB/c) mice were purchased from 
Taconic Farms, Inc. (Germantown, NY), housed under stan-
dard conditions and fed ad libitum. Mice were housed at NYU 
for one week prior to initiation of experiments.
Induction of IFn-γ
Spleens were aseptically harvested from eight-week old male 
BALB/c mice and teased into single cell suspensions. CD4+ 
cells were isolated using the Dynal® Mouse CD4 Negative 
Isolation Kit (Oslo, Norway) and added to 6-well plates from 
Fisher Scientific (Pittsburgh, PA) with DMEM supplemented 
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with 10% heat inactivated FBS and 1% pen/strep. CD4+ cells 
were treated with ultraviolet-inactivated supernatants from 
BHK-21 cells containing 500 pg of VSV23 induced IL-23 
(vIL-23). UV-inactivated supernatants containing 500 pg of 
virally induced IL-12 (vIL-12) from BHK-21 cells infected 
with a rVSV expressing IL-12, [the generous gift of Dr Savio 
Woo (Mt Sinai School of Medicine, New York, NY)] were 
also tested.60 500 pg of recombinant IL-23 (rIL-23) or rIL-12 
(R&D Systems Minneapolis, MN) were used to treat cells as 
positive cytokine controls and supernatant from untreated/
uninfected BHK-21 cells was used as a negative control. 
Samples were incubated at 37 °C and 5% CO
2
 for six hours 
and RNA was isolated with Trizol® reagent (Invitrogen, 
San Diego, CA). RNA was subjected to reverse transcriptase-
PCR for detection IFN-γ mRNA. The forward primer was 
5′-GCTTTGCAGCTCTTCCTCAT-3′ and the reverse primer 
was 5′-TGAGCTCATTGAATGCTTGG-3′. Beta actin was 
used as a housekeeping control for the reaction. The forward 
primer was 5′-AAGAGCTATGAGCTGCCTGA-3′ and the 
reverse primer was 5′-TACGGATGTCAACGTCACAC-3′.
NK assay
Cohorts of N = 6, six-week old male BALB/c mice were 
inoculated IP with 1 × 107 pfu of VSV23, VSVST, VSVXN2, 
VSVwt, or mock infected as a control. Three days later, spleens 
from individual mice were harvested, teased into a single 
cell suspension, and resuspended in MEM, 10% FBS, 1% 
Pen-Strep. 1 × 104 YAC-1 cells were plated in 96-well V-bottom 
plate wells in 100 µl of MEM supplemented with 10% FBS and 
1% Pen-Strep. Splenocytes were co-incubated with YAC-1 cells 
in triplicate at ratios of 200:1, 100:1, 50:1, 25:1, and 12.5:1, 
and 6.25:1 in a total volume of 100 µl. Plates were centrifuged 
at 200 × g for 5 minutes to improve contact between cells and 
incubated for four hours at 37 °C, 5% CO
2
. The CytoTox 
96TM nonradioactive cytotoxicity kit (Promega©, Madison, 
WI) was used per manufacturer’s instructions to determine 
NK mediated cytolytic activity. Results were read on a Biorad 
550 series microplate reader (Hercules, CA) at 490 nm. Results 
are representative of two replicate experiments.
CTL assay
Cohorts of N = 6, six-week old male BALB/c mice were 
injected IP with 1 × 107 pfu of VSV23, VSVST, VSVXN2, 
or VSVwt, to produce responder cells. Mock-injected mice 
were used as a negative control and as a source of naive 
controls for effector cells. Twenty days after immunization, 
spleens from individual mice were harvested, teased into a 
single cell suspension, and resuspended in MEM, 10% FBS, 
1% Pen-Strep. Stimulator cells were prepared by infecting 
naive splenocytes with VSV tsG41 at MOI = 5 at the permis-
sive temperature of 33 °C for one hour.37 Cells were washed 
in HBSS to remove unadsorbed virions. 5 × 106 responder 
cells were cultured with 1 × 106 VSV tsG41 stimulator cells 
or with uninfected stimulator cells for five days in DMEM, 
10% FBS, 1% Pen-Strep, 5 mM 2-mercaptoethanol, and 1% 
L-glutamine at 37 °C, 5% CO
2
. A20 cells (syngeneic H-2d 
MHC I and MHC II-expressing) were used as target cells.35,61 
Target cells were either infected with VSVwt at multiplicity 
of infection (MOI) = 3 or mock-infected and plated in 96 well 
V-bottom plates at 1 × 104 cells per well. Responder cells from 
individual mice of each treatment group were added to target 
cells in triplicate at effector to target ratios of 100:1, 50:1, 
25:1, and 12:1. Plates were centrifuged for five minutes at 
200 × g to improve cell contacts and incubated for four hours 
at 37 °C, 5% CO
2
. The CytoTox 96TM nonradioactive cytotox-
icity kit (Promega) was used per manufacturer’s instructions 
to determine T cell mediated cytolytic activity. Results were 
read on a Biorad 550 series microplate reader at 490 nm. 
Results are representative of two replicate experiments.
Proliferation assay
Cohorts of N = 6, six-week-old male BALB/c mice were 
inoculated IP with 1 × 107 pfu of VSV23, VSVST, VSVXN2, 
or VSVwt to produce responder cells. Mock-treated mice 
were used as a negative control. Twenty days later, spleens 
were harvested, teased into a single cell suspension, and 
resuspended in MEM supplemented with 10% FBS and 
1% Pen-Strep. Stimulator cells were prepared by treating 
naive spleen cells with five pfu of VSVtsG41 per cell at 
the permissive temperature of 33 °C for 1 hour. Cells were 
washed in HBSS to remove unabsorbed virions. 1 × 105 
responder cells from individual mice were seeded in a 
96-well plate, in triplicate, with either 1 × 105 of VSVtsG41 
infected or uninfected stimulator cells and allowed to 
incubate for 3 days in MEM supplemented with 10% FBS, 
1% Pen-Strep, 2-mercaptoethanol, and L-glutamine at 37 °C, 
5% CO
2
. The Cell Proliferation ELISA, BrdU (colorimetric) 
kit (Roche Diagnostics, Indianapolis, IN) was utilized 
per manufacturer’s instructions and the results read on a 
Biorad 550 series microplate reader at 490 nm. Results are 
representative of two replicate experiments.
Neutralization assay
Cohorts of N = 10, six-week old male BALB/c mice were 
infected in with 1 × 103 pfu of VSV23, VSVST, VSVXN2, 
or VSVwt. Uninfected animals were used as a control. 
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Blood samples were collected from the ocular plexus 20 days 
PI from surviving individual animals and allowed to clot 
overnight at 4 °C. Serum was diluted in PBS in serial five-fold 
steps. 1 × 103 pfu of VSVwt was added to each dilution and 
incubated at 37 °C 5% CO
2
 for 1 hour. Plaque assays were 
performed in triplicate samples on L929 cells and neutraliz-
ing antibody titers were calculated. Results are representative 
of three replicate experiments.
Viral titers and nitric oxide 
levels in CNS
Cohorts of N = 6, six week-old male BALB/c mice were 
infected IN with 1 × 103 pfu or 1 × 106 of VSV23, VSVST, or 
VSVXN2. Individuals were sacrificed on days 1, 3, 6, and 9 
PI and brains were divided sagittally. One half was reserved 
for immunohistochemical staining. The other brain half was 
individually homogenized, and an aliquot was serially diluted, 
and assayed in triplicate by plaque assay on L929 cells for 
the presence of VSV. Geometric mean titers were calculated 
for each cohort. Homogenate samples for NO assays were 
pre-cleared of solid material by centrifugation. The Total 
Nitric Oxide Assay Kit (Pierce, Rockford, IL) was used as 
per manufacturer’s instructions to convert nitrate to nitrite 
from individual samples. Equal volumes of experimental 
sample and Greiss reagent (1% sulfanilamide, 0.1% N-
1-naphthylethylene-diamine, and 5% H
3
PO
4
; Sigma-Aldrich, 
St. Louis, MO) were incubated in the dark at room tempera-
ture for 10 minutes and results were read on a Biorad 550 
series microplate reader at 540 nM.
Morbidity and mortality assay
Cohorts of N = 10, six-week old male BALB/c mice were 
infected in with 1 × 104 or 1 × 106 pfu of VSV23, VSVST, 
VSVXN2, or VSVwt and monitored daily for 15 days. Mice 
were weighed daily. Hind-limb paralysis or weight loss that 
exceeded 30% of starting weight were considered end points 
for the experiment. Mice were individually scored blind on 
a subjective six point scale (0–5): “0” for no symptoms, 
“1” for lack of grooming behavior, “2” for hunched and 
severely lethargic mice, “3” for hind-limb paralysis, “4” for 
full paralysis, and “5” for deceased. The experiment was 
single-blinded.
In vitro infection of target jC cell
JC cells were seeded in 96-well plates at a concentration 
of 4.5 × 104 and incubated overnight at 37 °C, 5% CO
2
. Six 
replicate wells were used for each treatment condition and 
time point. Cells were then infected at MOI = 3.0 with VSV23, 
VSVST, VSVXN2, or VSVwt and incubated at 37 °C 5% CO
2
 
for 3, 6, 9, 12, 18, or 24 hours. Mock infected cells were used 
as a negative control. The TACS MTT Cell Proliferation Assay 
(R&D Systems Minneapolis, MN) was used per manufacturer’s 
instructions to conduct the assay. Samples were read at 
540 nM on a Biorad 550 series microplate reader.
Statistical analysis
GraphPad Prism statistical software (GraphPad Software 
Inc., La Jolla CA) was used for ANOVA, Kruskal–Wallis, 
Student’s t-test, and Kaplan–Meier statistical analyses.
Results
Recombinant VSV construction  
and characterization
In order to produce a rVSV that expresses IL-23, the cDNA of 
a single chain IL-23 (scIL-23) comprised of the p40 and p19 
subunits joined by a flexible linker was cloned into the pXN2 
plasmid (Figure 1A) to produce the pXN2-scIL23 plasmid 
(Figure 1B). IL-23 was chosen for its proinflammatory and 
intrinsic oncolytic properties. The reverse genetics method 
described by the Rose lab was used to produce VSV23.59 
To control for attenuation of VSV resulting from altera-
tions in genome size and particle morphology, two control 
viruses were produced utilizing the same reverse genetics 
approach. The first, VSVST, was generated by insertion of a 
mutagenized cDNA for IL-23 that contained three stop con-
dons in the p40 subunit into pXN2 (Figure 1C). The second, 
VSVXN2, was rescued with an unaltered pXN2 plasmid.
If VSV23 were to have impaired replication kinetics, 
this would be adverse to the intended use for oncolysis. 
In order to determine if the kinetics of VSV23 infection were 
similar to VSVwt and controls, a one-step growth curve was 
conducted in L929 cells. At all time points, viral titers were 
comparable, indicating that genome alterations do not result 
in diminished infectivity or reduced replication capacity 
(Figure 2). Data are representative of three replicate experi-
ments and expressed as means ± standard deviation.
To determine if IL-23 were secreted by VSV23 infected 
cells, but not by cells infected with control viruses, we tested 
supernatants with an ELISA specific for the p40 subunit if 
IL-23. BHK-21 cells were infected at MOI = 0.1 and incu-
bated for 24 hours. Only supernatants from VSV23 infected 
cells contained detectable levels of IL-23 (Figure 3A). Stop 
codons inserted into the p40 subunit of IL-23 in the VSVST 
viral genome successfully prevented transcription, translation 
and secretion of IL-23, thus validating the use of this virus 
as a control.
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Among concerns about the efficacy of VSV23, was 
the ability to produce an active cytokine. To determine the 
bioactivity of virally induced IL-23 (vIL-23), isolated CD4+ 
cells were treated with vIL-23 and probed for IFN-γ mRNA. 
CD4+ cells were isolated from spleens of male BALB/c mice 
and incubated with supernatants from BHK-21 cells that 
had been infected for 24 hours with VSV23. Supernatants 
from BHK-21 cells that had been infected with a rVSV that 
expresses IL-12 were used as a positive control, along with 
commercially available IL-23 and IL-12. Mock infected cells 
and BHK-21 cells which were infected with VSVST or with 
VSVXN2 did not induce IFN-γ mRNA (data not shown). 
Nucleotide-1
pUC ampR
N
P
M
G
L pXN2
14665 bp
A B
pUC
ampR
N
P
G
sclL23
L pXN2sclL23
16191 bp
M
C
pUC
ampR
N
P
G
sclL23
L pXN2sclL23ST
16191 bp
M
Figure 1 Virus production plasmids. A) VSVXN2. is a plasmid map of the 14.6 kb pXN2 plasmid that serves as the cloning vector in the recombinant VSV system and used 
for the rescue of VSVXN2. B) VSV23. A single chain IL23 was created by linking the coding regions for the p40 and p19 subunit with a flexible linker and inserted in the pXN2 
expression vector at the XhoI/NheI mcs. The resultant plasmid was designated pXN2scIL23 and used for the rescue of VSV23. C) VSVST. Point mutations were induced in 
the pXN2scIL23 plasmid to introduce 3 stop codons in the p40 subunit coding region. This plasmid was used in the rescue of VSVST.  All three plasmids were subsequently 
co-transfected into BhK-21 cells with 3 helper plasmids individually coding n, P, and L. A previous infection of vaccinia virus provides the T7 polymerase for expression of the 
viral genes in the cytoplasm of the cells.
Abbreviation: MCs, multiple cloning sites.
P
F
U
/M
L
1.00E + 09
1.00E + 08
1.00E + 07
1.00E + 06
1.00E + 05
1.00E + 04
1.00E + 03
1.00E + 02
1.5 3 6
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12 24
VSV23
VSVXN2
VSVST
VSVwt
Figure 2 One-step growth curve:  VSV23 (diamond), VSVST (circle), VSVXN2 (square), and VSVwt (triangle) were used to infect L929 cells at an MOI = 1 in triplicate. Media 
samples were removed at 1.5, 3, 6, 12, and 24 hours and stored at -80 °C. Virally infected supernatants were serially diluted and transferred to fresh L929 cells for plaques assay. 
growth kinetics for all viruses are similar at all time points. Data presented are geometric means ± standard deviation and are representative of three replicate experiments.
Abbreviations: PI, post infection, MOI, multiplicity of infection;  VSV, vesicular stomatitis virus.
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IL-12 treated cells showed IFN-γ mRNA expression at 
12 and 18 hours (lanes 3 and 5, respectively, Figure 3B), but 
IL-23 treated cells only showed a positive signal at 18 hours 
(lane 6). vIL-12 treatment induced a strong signal at 12 and 
18 hours (lanes 9 and 11, respectively), while vIL-23 treated 
cells again induced IFN-γ message at 18 hours (lane 12). Data 
presented are representative of three replicate experiments. 
From this we conclude the VSV23 does encode a functional 
IL-23 cytokine.
VSV23 induces robust immune 
responses in the periphery
Use of VSV23 as an oncolytic agent requires that the virus be 
capable of inducing immune responses necessary to protect 
noncancerous tissues from viral infection. Immunization of 
groups of mice with the panel of viruses was performed to 
determine if VSV23 were immunogenic in vivo following 
parenteral exposure. Subsequently, we evaluated nonantigen 
restricted innate immune responses, as well as antigen-
specific targeted CTL and memory responses, and antibody 
production induced by VSV23 inoculation and infection.
nK assay
Viral infection or immunization is one of the most effective 
ways to induce NK cells, an innate immune response to 
infection which is not antigen-specific nor histocompatibility-
restricted.62 NK lytic activity can be quantified by measuring 
lysis of sensitive cells such as YAC-1.63 NK activation was 
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Figure 3 VSV23 Produces Active IL-23. A) vIL23 production by VSV23 infected BHK21 cells. BHK21 cells were infected with VSV23, VSVST, or  VSVXN2 at MOI = 0.1 and 
incubated overnight at 37 °C. Virally infected supernatant was harvested and subjected to UV inactivation to inactivate virus. Supernatant from uninfected BHK21 cells was 
used as a negative control. Samples were subjected to the Quantikine Mouse IL-12/IL-23 p40 (non-allele-specific) Immunoassay ELISA kit (R&D Systems Minneapolis, MN). 
Supernatant from VSV23 infected cells contained 750 pg/ml of the p40 subunit. The experiment indicates that there are no detectable levels of p40 secreted by cells infected 
with VSVST or VSVXN2. BHK21 cells do not produce IL-23 and as expected control samples did not produce detectable levels of the cytokine component. B) IFn-γ is induced 
by IL-23: Lanes represent amplified mRNA specific for IFN-γ from CD4+ cells that were treated as follows –1: rIL-12 for 6 hours, 2: rIL-23 for 6 hours, 3: rIL-12 for 12 hours, 4: 
rIL-23 for 12 hours, 5: rIL-12 for 18 hours, 6: rIL-23 for 18 hours,7: vIL-12 for 6 hours, 8: vIL-23 6 hours, 9: vIL-12 for 12 hours, 10: vIL-23 for 12 hours, 11: vIL-12 for 18 hours, 
12: vIL-23 for 18 hours, 13: untreated CD4+ T cells. Upper band represents IFn-γ signal at 400 bp, lower band is gAPDh loading control at 200 bp. each reaction was run in 
triplicate, and the experiment was repeated twice. Image is typical of all results.
Abbreviations: IFn, interferon; mRnA, messenger ribonucleic acid.
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tested 3 days post-inoculation with the panel of viruses. 
Splenocytes from individual donors were tested separately. 
Both mock and uninfected splenocytes showed similar 
background levels of cell lysis indicating no NK mediated 
cell killing in either of these infection groups (Figure 4A). 
Data are representative of 3 replicate experiments; data are 
expressed as means ± standard deviation of 6 individuals 
per group. The NK cytolytic responses elicited by VSV23 
inoculation were indistinguishable from those induced by 
VSVST, VSVXN2, and VSVwt.
CTL assay
The ability of viruses to elicit host CTL responses which 
control infection and promote recovery is a hallmark of 
host acquired immunity to infection. A secondary CTL 
experiment was conducted to determine VSV specific rec-
ognition of syngeneic target cells 20 days after immuniza-
tion of mice with the panel of viruses. There was no lysis 
of uninfected A20 cells, and virus infection of stimulator 
cells was required to induce CTL activity (data not shown). 
All splenocytes cultured with VSV tsG41(a temperature 
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Figure 4 Innate and adaptive immune responses to VSV23. A) natural killer cell activation: Cohorts of N = 6 week old male BALB/c mice were inoculated ip with 1 × 107 
pfu of VSV23 (diamond), VSVST (circle), VSVXN2 (square), VSVwt (triangle), or vehicle (square and dashed line). Uninfected animals were used as a control (circle and dashed 
line). splenocytes were harvested 3 days later and co-incubated with YAC-1 cells. Cytolytic activity was determined using the CytoTox 96® nonRadioactive Cytotoxicity 
Assay from Promega. All samples from virally inoculated animals showed similar levels of nK mediated cell killing. Data presented are means ± standard deviation and are 
representative of three replicate experiments. B) Memory response against VSV is shown in splenocytes targeted to VSV infected A20 cells: Cohorts of N = 6 week old male 
BALB/c mice were injected ip with 1 × 107 pfu of VSV23 (diamond), VSVST (circle), VSVXN2 (square),  VSVwt (triangle), or mock infected (square and dashed line). Cultured 
T cells from uninfected animals were used as a negative control (circle and dashed line). 20 days post inoculation, splenocytes were harvested and cultured with stimulator 
splenocytes either infected with VSVtsG41 or uninfected (data not shown).  After 5 days of incubation, cells were incubated with A20 tumor cells that were either infected with 
tsg41 or not infected. All splenocytes cultured with tsg41 infected stimulators exhibited cytolytic activity against infected A20 cells, indicative of a memory response against 
VSV. Data presented are means ± standard deviation and are representative of three replicate experiments. C) All virus-immune T cell populations show T cell proliferation 
when cultured with infected stimulators. Cohorts of N = 6, 6 week old male BALB/c mice were inoculated ip with 1 × 107 pfu of VSV23, VSVST, VSVXN2, VSVwt, or mock 
infected. Uninfected animals were used as a control. Twenty days after immunization, splenocytes were harvested and cultured with syngeneic stimulator splenocytes that 
were infected with VSVtsG41 (at the permissive temperature, 31 °C; left panel) at a ratio of 1:1. Triplicate cultures were incubated for 3 days. T cell proliferation was then 
measured using the BrdU eLIsA Assay Kit from Roche Applied science. Data are presented as mean ± standard deviation. All splenocytes cultured with VSVtsG41-infected 
stimulators showed similar levels of T cell proliferation, while those cultured with uninfected stimulators (data not shown) indicated no proliferation above the background 
of mock-infected or uninfected control CD4+ cells (data not shown). Data presented are means ± standard deviation. The experiment shown is one of three replicate studies, 
with comparable results. D) Neutralizing antibodies are present 20 days post infection. Cohorts of N = 6 week old male BALB/c mice were infected in with 1 × 103 pfu of 
VSV23, VSVST, VSVXN2, or VSVwt. Uninfected animals were used as a control. Blood samples were collected 20 days post infection. Serum was isolated and serial five-fold 
dilutions were made. 1 × 103 pfu of each virus was co-incubated with the serum from the matching treatment group for one hour. samples were then used to infect L929 
cells and plaque assays were subsequently performed and used to determine antibody titer. Data presented are geometric means ± standard deviation and are representative 
of three replicate experiments. All viral treatment groups showed similar levels of neutralizing antibodies to rVSVs.
International Journal of Interferon, Cytokine and Mediator Research 2009:1 23
Cytokine-modified VSV: its utilization as an oncolytic agentDovepress
submit your manuscript | www.dovepress.com
Dovepress 
sensitive VSV mutant) infected stimulators developed CTL 
activity against VSV-infected A20 cells, indicative of a 
memory response against VSV (Figure 4B). Data shown are 
representative of 3 replicate experiments and are expressed as 
means ± standard deviation of 6 individuals per condition. This 
experiment indicated that VSV23 was capable of inducing 
VSV-specific memory CTLs.
Proliferation assay
The ability of viruses to induce memory specific Th1 cell 
responses is often measured by the induction of antigen-
specific proliferating cells with syngeneic antigen presenting 
cells (APCs). A proliferative response to VSV antigens by 
T cells was determined for the panel of viruses twenty days 
after injection. The ability of VSV23 and control viruses 
to induce memory responses was indistinguishable from 
VSVwt (Figure 4C). All responder CD4+ T cells incubated 
in the absence of VSVtsG41 showed no proliferation above 
background, similar to that seen in cells from naïve mice with 
VSV-infected APCs (data not shown). The data shown are 
representative of 3 replicate experiments. Data are expressed 
as means ± standard deviation of 6 individuals per condition. 
We interpret these data to indicate that VSV23 induced a 
robust CD4+ memory response.
Neutralizing antibody assay
The ability to induce the production of neutralizing antibody 
is critical for protection against secondary viral infections. 
Groups of mice were infected IN with the panel of the 
viruses, and surviving individuals were bled twenty days 
after immunization to obtain serum. Serum of individual 
donors was diluted in PBS in serial five-fold steps. 1 × 103 
pfu of VSVwt in PBS was added to each dilution and all 
samples were allowed to incubate for 1 hour before adsorp-
tion to L929 monolayers. Three replicate experiments were 
performed with similar results. Data are expressed as means ± 
standard deviation of six individuals per group. All 4 virus 
immunizations produced similar results (Figure 4D), which 
indicated that VSV23 was able to stimulate the production 
of neutralizing antibodies against VSVwt.
VSV23 is attenuated for encephalitis 
and induces no responses
A potential concern regarding the use of VSV as an oncolytic 
agent is the characteristic encephalitis that results from 
infection of the CNS in immunocompetent mice. Adminis-
tration of VSV IN results in infection of olfactory sensory 
neurons in the nasal turbinates. The infection spreads along 
the olfactory nerve to the olfactory bulb and then caudally 
through synapses. Once VSV reaches the olfactory ventricle, 
virus spreads in cerebral spinal fluid to motor neurons in 
the lumbar-sacral spinal cord, giving rise to the symptoms 
of encephalitis and hind-limb paralysis in the infected 
animal.16,64,65
The ability of VSV23 to cause disease in mice when 
administered IN (the route which readily leads to viral 
encephalitis) was studied. VSV23 was compared with the 
rVSV controls and VSVwt for the ability to cause illness and 
death. Specific immune responses in the CNS in response to 
infection, as well as resultant viral titers, were determined.
Decreased morbidity and mortality at 1 × 104 pfu
Cohorts of mice were infected IN with the panel of viruses 
and examined daily (by an observer who was blinded to the 
challenge viruses) for 15 days to monitor for weight loss and 
health. Hind-limb paralysis or weight loss that exceeded 30% 
of starting weight were considered end points for individu-
als in the experiment. Three replicate experiments indicated 
that VSV23 was completely attenuated in the CNS at 1 × 104 
pfu. Mice receiving the recombinant viruses at those doses 
exhibited 20% mortality while mice infected with VSVwt 
exhibited 70% mortality (Figure 5). Kaplan-Meier survival 
curve analysis indicated that VSV23 was different from the 
other rVSVs by p  0.05 and from VSVwt by p  0.005.
Decreased morbidity and mortality at 1 × 106 pfu
To determine the extent and mechanism of attenuation, 
the infection was performed at a much higher challenge, 
1 × 106 pfu. This dose was chosen based on pilot studies 
utilizing increasing log doses to determine the minimum pfu 
of VSV23 that could induce mortality.
Cohorts of mice were infected IN with the panel of viruses 
and examined daily (by an observer who was blinded to the 
challenge viruses) for 15 days to monitor for weight loss 
and health. Hind-limb paralysis or weight loss that exceeded 
30% of starting weight were considered end points for indi-
viduals in the experiment. The nonparametric Kruskal-Wallis 
analysis of symptom data showed a significant difference in 
clinical scores among the groups (p  0.05), indicative of 
the decreased morbidity characteristic of VSV23 infection 
(Figure 6A). Analysis of average percentage weight loss for 
all groups indicated no significant difference in weight among 
all infection groups (Figure 6B). VSV23 infection resulted 
in 25% mortality. Infection with VSVST and VSVXN2 
resulted in 40% and 58% mortality, respectively (Figure 6C). 
Kaplan-Meier survival curve analysis utilizing the one-tail 
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p value indicated that VSV23 was different from the other 
viruses by p  0.05. Taken together, these experiments 
indicate that VSV23 is attenuated for both morbidity and 
mortality in mice.
VSV23 titers in the CNS
A simple way to quantify the degree of VSV23 attenuation is 
to measure viral titers in the brains of infected animals. Mice 
were infected IN with the panel of viruses and on days 1, 3, 
6, and 9 after infection, virus present in homogenates of 
brain tissue from individuals were tested by plaque assay. 
Viral titers of VSV23 infected mice were approximately 
10- to 100-fold less than both VSVST and VSVXN2 at all 
time-points in the CNS after IN infection with 1 × 103 pfu 
(Figure 7A). Brains of animals infected with 1 × 106 pfu 
of VSV23 contained similar viral titers on days 1 and 3 PI 
compared to control viruses (Figure 7B). We interpret this to 
indicate that at the lower challenges, the secretion of IL-23 
enhanced the attenuation of the virus infection of neurons.
VSV23 infection of the CNS induces increased  
levels of nitric oxide
Studies have shown that production of nitric oxide (NO) in the 
CNS promotes survival and recovery from VSV encephalitis.66–68 
In addition, IL-12 promotes rapid containment of virus in 
the CNS and enhanced survival.69–71 In experiments in vitro, 
VSV23, but not the other viruses induced neuronal cells (but 
not fibroblasts) to produce NO which subsequently suppressed 
viral replication (data not shown). Therefore, it was important 
to determine if VSV23 were able to induce the production of 
NO in vivo during infection of the CNS. Mice were infected 
IN with the panel of viruses and on days 1, 3, 6, and 9 after 
infection, homogenates of brain tissue from individuals were 
examined for the presence of NO by a colorimetric test, the 
Greiss assay. Although there was no significant increase in 
NO levels day 1 PI, by day 3 VSV23 infection resulted in 
significantly increased NO levels, at both infection doses. 
Measurement of NO levels indicated a significant increase in 
NO in VSV23 infected animals compared to control viruses 
after infection with 1 × 106 pfu VSV23, p  0.05 as determined 
by ANOVA analysis (Figure 7C). We interpret these data to be 
compatible with the hypothesis that IL-23 induces nitric oxide 
synthase (NOS) activation and NO production in vivo.
VSV23 replicates in tumor cells in vitro  
and induces apoptosis
VSV infection of susceptible cells rapidly leads to apoptosis 
due to both blockade of the nuclear pore complex and direct 
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Figure 5  VSV23 infection is attenuated for lethal intranasal infection resulting in viral encephalitis at 1 × 104 pfu: Cohorts of N = 10, 6-week old BALB/c mice were infected 
intranasally with 1 × 104 pfu of VSV23, VSVST, VSVXN2, or VSVwt and monitored for 15 days. VSV23 infection resulted in no mortality,  VSVST infection resulted in 20% mortality, 
VSVXN2 infection resulted in 20% mortality, and VSVwt resulted in 70% mortality.  VSV23 is different from the other recombinant viruses by p  0.05 and from VSVwt by 
p  0.005 in Kaplan Meier analysis. Results were identical in three replicate experiments.
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Figure 6 VSV23 infection is attenuated for lethal intranasal infection resulting in viral encephalitis at 1 × 106 pfu: Cohorts of N = 10, 6-week old BALB/c mice were infected 
intranasally with 1 × 106 pfu of VSV23, VSVST, or VSVXN2 and monitored for 15 days. A) Morbidity: Mice were weighed and scored daily to assess clinical symptoms: “1” for 
lack of grooming behavior, “2” for hunched and severely lethargic mice, “3” for hind-limb paralysis and “4” for full paralysis, “5” for death. each data point represents the average 
score of the cohort. Kruskal-Wallis analysis of symptom data indicated that VSV23 exhibited a significant difference in clinical scores p  0.05. B) Weight-loss:  Weight-loss was 
comparable for all infection groups and is presented as mean ± standard deviation. C) Mortality:  VSV23 infection resulted in 25% mortality, VSVST infection resulted in 40% 
mortality,  VSVXN2 infection resulted in 58% mortality.  VSV23 is different from the other viruses by p  0.05 in Kaplan Meier analysis.
Abbreviation: PI, postinfection.
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Figure 7 rVSV viral titers and NO production following intranasal infection:  A) Viral titers at 1 × 103 pfu: Cohorts of n = 6, 6 week old male BALB/c mice were infected 
in with 1 × 103 pfu of VSV23, VSVST, or VSVXN2. Brains were harvested on days 1, and 3 p.i., divided into hemispheres sagitally, and one half was homogenized. Samples 
were serially diluted and plated on L929 cells. Plaque assays were performed cells to determine viral titers. Data points represent titers in individual mice. Horizontal bars 
indicate the geometric mean titer of the cohorts. VSV23 titers as represented by the geometric mean were at least 1 log lower than all other viral treatment groups at both 
time points. B) Viral titers at 1 × 106 pfu: The experiment out lined above was repeated, but mice were infected in with 1 × 106 pfu of VSV23, VSVST, or VSVXN2. Results were 
similar for all infections at both time points. Data shown are representative of 3 identical experiments. C) nO levels in the central nervous system: Brains were harvested on days 
1, 3, 6, and 9 p.i. after infection with VSV23 (solid bars), VSVST (stipled bars), VSVXN2 (slashed bars), or mock infected (plaid bars) and homogenates were tested for the presence 
of NO using the Greiss assay. VSV23 induces greater amounts of NO compared to other rVSVs and does so at earlier time points. Data shown are means ± standard deviations. 
ANOVA analysis of days 3 and 6 data reject the null hypothesis with p  0.05. This figure is representative of data from three identical experiments.
Abbreviation: nO, nitric oxide.
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interactions with the mitochondria.6–8,72 In order to test the 
ability of VSV23 to infect and kill tumor cells, the panel of 
viruses was used in an in vitro growth study in a murine mam-
mary derived JC tumor line. Cells were infected and an assay 
of apoptosis, the MTT assay, was conducted at 3, 6, 9, 12, 18, 
and 24 hours PI. Experimental results (Figure 8) indicated 
that VSV23 replicated and induced JC cell death that was 
indistinguishable from control rVSVs and VSVwt.
Discussion
VSV selectively destroys a wide variety of tumor cell lines 
including those with aberrant p53, Ras, or Myc function such 
as glioblastomas10,73,74 colorectal, pancreatic, and breast cancer 
cells.24,75–77 Other targets of VSV therapy include leukemia, 
hepatocellular carcinoma, nasopharyngeal carcinoma, and 
bladder cancer.75,78–85 Several characteristics of VSV make 
it particularly attractive as a candidate for development as 
an oncolytic virus. VSV has a rapid replication cycle and 
infection with VSV is generally both asymptomatic and 
very rare in humans.86 Potentially, VSV could replicate and 
exert its oncolytic effects prior to host development of a 
neutralizing serological response.75 Finally, the virus can 
easily be genetically engineered to express transgenes.59,87–90 
However, administration of therapeutic doses of VSV in mice 
can lead to substantial “toxicities” including hind-limb paraly-
sis and death.10,24 The need to create a safer oncolytic agent 
and our extensive prior studies on the pathogenesis of VSV 
encephalitis led to the hypothesis that a rVSV that expresses 
IL-23 would attenuate the virus in healthy tissue while main-
taining and possibly enhancing oncolytic activity.16,26,65,91–93
This hypothesis was based on several lines of research. 
In studies of VSV encephalitis, treatment of mice with IL-12 
enhances viral clearance and survival.70,71,94 Unfortunately, 
administration of IL-12 in phase II clinical oncology trials 
has been associated with severe toxicity and death, partly due 
to the induction of high levels of IFN-γ.53,54 Since IL-23 and 
IL-12 share the functional p40 subunit and a receptor chain 
component, IL-12Rβ1, IL-23 was anticipated to act in similar 
manner, however with reduced deleterious effects. This is 
due to the fact that IL-23 induces lower levels of IFN-γ than 
IL-12.43 Additionally, IL-23 is expressed in the CNS during 
inflammation.43,46,95 Finally, IL-23 has been reported to have 
antimetastatic and antitumor properties.49,52,55–57,96 Experi-
ments in murine mammary cancer cells have shown that these 
IL-23 effects are mediated by increasing numbers of CD4+ 
T cells and induction of tumor specific CD8+ T cells.57
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Figure 8 Infection with VSV23 and VSVXN2 induces mitochondrial dysfunction in JC cells: 4.5 × 104 JC cells were plated in 96-well plates and incubated overnight. Cells were 
then infected at MOI = 3 and incubated for 3 (solid bars), 6 (stipled bars), 9 (slashed bars), 12 (horizontal striped bars), 18 (vertically striped bars), or 24 (plaid bars) hours 
with VSV23,  VSVST,  VSVXN2,  VSVwt, or mock treated. MTT reagent was added per manufacturer’s instructions and samples were incubated at RT in the absence of light for 
4 hours. Plates were read on an eLIsA plate reader at 540 nm.  All viruses are capable of disrupting mitochondrial function. Data are presented as mean ± standard deviation 
and are representative of the replicate experiments.
Abbreviation: RT, room temperature.
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We presented data showing that a rVSV, designated 
VSV23, expresses functionally active IL-23 and maintains 
replicative capacity. A concern in using a scIL-23 cDNA is 
that translation of the subsequent mRNA might not result in 
an active protein. However, virally produced IL-23 readily 
induced IFN-γ mRNA in CD4+ T cells (Figure 3B). Addition 
of 1.3 kb of RNA into the VSV genome could have resulted in 
significant deficiencies in viral replication; however one-step 
growth curve data showing similar viral titers between control 
viruses and VSV23 ameliorated this concern (Figure 2).
In order for VSV23 to be a safe oncolytic agent, the 
virus must be capable of inducing innate and adaptive host 
immune responses in order to prevent infection of the CNS 
and subsequently inducing encephalitis. Bystander effects 
including cellular immunity and antitumor responses that 
result in tumor destruction caused by VSV23 infection are 
also hypothesized to be beneficial in the treatment of cancer. 
To determine if VSV23 were sufficiently immunogenic, 
a series of experiments were conducted to examine innate 
and adaptive immune responses.
Innate NK cell activity does not require exposure to a spe-
cific antigen in order to elicit a cytolytic response.63 Activation 
only requires local immune responses that stimulate IFN-γ, 
IL-12, and other cytokines that result in positive regulation 
of NK cells.97 Inoculation of mice with VSV23 induced 
similar levels of NK mediated YAC cell killing three days PI 
compared to control rVSVs and VSVwt (Figure 4A). Studies 
have shown that IL-23 takes up to 2 weeks after the initiation 
of treatment to enhance the effect of NK cells.49
Adaptive immune responses to viral infection can be 
detected in mice as early as 7 days PI. Memory responses 
in mice inoculated with the panel of viruses were assayed 
twenty days after inoculation and were indistinguishable 
(Figs 4B–D). Studies using unprimed lymphocytes indicated 
no memory response. This was due to insufficient precursors 
in naïve mice. There was a similar level of memory responses 
in VSV23 primed mice as indicated by comparable levels of 
CTL activity at all effector-to-target ratios. The proliferation 
of T cells is an important property of the adaptive immune 
system.98 The proliferative response to the VSV antigens by 
CD4+ T cells was determined. As expected, all virus-primed 
splenocytes cultured with VSV tsG41-infected stimulators 
showed similar levels of T cell proliferation (Figure 4B). 
In addition to cell mediated responses to viral inoculation, 
we examined the production of neutralizing antibodies after 
IN infection. Twenty days PI, comparable levels of neutral-
izing antibodies were detected in blood serum of infected 
animals (Figure 4D).
The results of assessments of adaptive immunity to VSV 
indicated that there was no difference in the ability of any 
of the viruses to induce adaptive immune responses. There 
was a possibility that vIL-23 would induce altered T cell 
responses. The fact that no differences in CTL killing, T cell 
proliferation, nor neutralizing antibody titers were observed 
could be explained by rapid viral clearance. There was sim-
ply insufficient time to produce biologically relevant levels 
of vIL-23 following IP inoculation. In the case of antibody 
production, vIL23 did not enhance B cell clones specific for 
VSV. Alternatively, it is possible that the antibody responses 
to other viral antigens were altered but undetected as we only 
assessed neutralizing antibody.
In vivo studies showed that VSV23 is attenuated for induc-
tion of viral encephalitis compared to control rVSVs and 
VSVwt. These results are consistent with previous findings 
that recombinant versions of VSV show greater attenuation 
in vivo compared to VSVwt.99–101 The reasons for attenuation 
are likely deletions and nucleotide variations characteristic 
of the cloned version of VSV.59 In order to control for the 
inherent differences in rVSVs compared to VSVwt we uti-
lized VSVXN2, a rVSV carrying no insert at the cloning site. 
VSVST was created to control for alterations in genome, and 
hence particle size associated with insertion of scIL-23. Stop 
codons were introduced into the p40 subunit coding region of 
IL-23, but not the p19 subunit. Infection of mice with VSV23 
led to decreased morbidity and mortality compared to mice 
infected with control viruses at a very high challenge dose 
(Figure 6A–C), but virtually none at lower challenges (data 
not shown) indicating that the attenuation of VSV23 can be 
attributed to the effects of vIL-23. Despite increased survival 
(Figures 5 and 6C) and milder symptoms in VSV23 infected 
mice (Figure 6 A, B), no difference was seen in weight loss 
indicating that infection with VSV23 results in some morbid-
ity. This may be due to transient destruction of the olfactory 
neuroepithelium leading to a decrease in olfactory function 
and hence decreased feeding activity.65 Minor differences in 
the attenuation of VSVST compared to VSVXN2 are likely 
due to morphological and metabolic alterations associated 
with the additional genomic load. Alternatively, it is pos-
sible (but unlikely) that residual expression of p19 might 
have led to induction of IFN-γ resulting in some attenuation 
in vivo.43
Measurement of viral titers in the CNS revealed a signifi-
cant decrease in VSV23 compared to control viruses after 
infection with 1 × 103 pfu (Figure 7A). Animals infected 
with 1 × 106 pfu of VSV23 had less morbidity and mortality, 
however this did not correlate to a decrease in viral titers on 
International Journal of Interferon, Cytokine and Mediator Research 2009:1 29
Cytokine-modified VSV: its utilization as an oncolytic agentDovepress
submit your manuscript | www.dovepress.com
Dovepress 
days 1 and 3 PI (Figure 7B). It is possible that at this early 
stage in the infection innate immune responses are being 
overwhelmed, but are subsequently capable of controlling the 
infection at later time points. Another hypothesis is that the 
spread of the virus in the CNS is limited in VSV23-infected 
animals. This would allow for high viral titers without infec-
tion of caudal regions of the brain. Work is in progress to 
address this question.
We hypothesized that vIL-23 may share the ability of 
IL-12 to induce NOS in the CNS, resulting in enhanced NO 
production.67,92,102 This would provide a plausible mecha-
nism of attenuation. After infection with 1 × 103 and 1 × 106 
pfu there was no significant increase in NO levels day 1 PI 
as determined by the Greiss assay. However, by day 3 PI 
significantly increased levels were detected (Figure 7B). 
Preliminary immunohistological analysis of sections from 
the olfactory bulbs of infected animals show that NOSII 
expressing microglia were present in VSV23 infected mice 
as early as 1 day PI, but not in other infections until day 6 
PI (data not shown). As such, increased levels of NOS II 
expressing cells between days 1 and 3 PI are likely to be 
responsible for the increase in NO levels in brain homog-
enates. Work continues at this time to determine whether 
increased NO levels can be attributed to any particular 
isoform of NOS in the CNS.
The purpose of creating VSV23 was to develop the virus 
as an oncolytic agent a vaccine carrier. To study the antitumor 
effects of the virus we have chosen the JC tumor cell, a murine 
mammary tumor cell line. In vitro, the ability of VSV23 to 
induce apoptosis in JC cells is indistinguishable from control 
rVSVs and VSVwt. Work is in progress to determine the 
whether VSV23 destroys tumors in vivo. Ideally vIL-23 pro-
duced within the tumor will induce a proinflammatory state 
that would increase oncolytic activity of the virus resulting 
in enhanced rates of tumor destruction. We will also deter-
mine if long-term memory responses are elicited specifically 
against JC tumor cells as a result of vIL-23. Examination of 
tumors to detect viral antigens and infiltrating immune cells 
will also help to determine the potential of VSV23 as an 
effective tumor treatment.
In conclusion VSV23 is an attenuated virus in vivo, but 
not in vitro. In the CNS, VSV23 infection is characterized 
by decreased morbidity and mortality, likely through the 
induction of early NO responses. In the periphery VSV23 
promotes a strong antigenic response based on the results of 
the virus-specific proliferation, CTL, neutralizing antibody, 
and NK assays. In vitro VSV23 is capable of inducing apop-
tosis in tumor cells. This oncolytic capacity coupled with 
attenuation in the CNS makes VSV23 an attractive agent for 
further study as on oncolytic virus.
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